The classical psychedelic drugs, including psilocybin, lysergic acid diethylamide and
mescaline, were used extensively in psychiatry before they were placed in Schedule I of the …

Research into the basic effects and therapeutic applications of psychedelic drugs has grown
considerably in recent years. Yet, pressing questions remain regarding the substances' …

Aims: The experience of a compromised sense of “self”, termed ego-dissolution, is a key
feature of the psychedelic experience. This study aimed to validate the Ego-Dissolution …

Rationale Major depressive disorder is one of the leading global causes of disability, for
which the classic serotonergic psychedelics have recently reemerged as a potential …

Mental disorders are rising while development of novel psychiatric medications is declining.
This stall in innovation has also been linked with intense debates on the current diagnostics …

The phenomenon of 'microdosing', that is, regular ingestion of very small quantities of
psychedelic substances, has seen a rapid explosion of popularity in recent years …

Lysergic acid diethylamide (LSD) was studied from the 1950s to the 1970s to evaluate
behavioral and personality changes, as well as remission of psychiatric symptoms in various …

Psychedelic Harm Reduction and Integration (PHRI) is a transtheoretical and
transdiagnostic clinical approach to working with patients who are using or considering …

To date, pharmacological treatments for mood and anxiety disorders and for drug
dependence show limited efficacy, leaving a large number of patients suffering severe and …

Rationale A broad reassessment of the potential benefits of psychedelic drugs has led to the
initiation of multiple major clinical trials in an effort to advance their status to become FDA …